Combined treatment reduced colitis inflammation by neutralizing TNF-α and blocking TNFR1, down-regulating colonic expression of TNF-α by disrupting positive feedback and the gene expression of IL-1β and IL-8 in peritoneal macrophages. This evidence concerns the gene IL1B and colitis.